Should I buy or sell Sage Therapeutics stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 1 sell rating, 13 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares. View SAGE analyst ratings or view top-rated stocks .

What is Sage Therapeutics' stock price target for 2024?

17 Wall Street analysts have issued 12-month price objectives for Sage Therapeutics' shares. Their SAGE share price targets range from $14.00 to $294.00. On average, they predict the company's stock price to reach $39.28 in the next twelve months. This suggests a possible upside of 189.2% from the stock's current price. View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts .

How have SAGE shares performed in 2024?

Sage Therapeutics' stock was trading at $21.67 at the beginning of the year. Since then, SAGE stock has decreased by 37.3% and is now trading at $13.58. View the best growth stocks for 2024 here .

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our SAGE earnings forecast .

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.28) by $0.73. The biopharmaceutical company had revenue of $77.97 million for the quarter, compared to analyst estimates of $60.15 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 54.41% and a negative net margin of 626.32%. The firm's revenue was up 2621.5% compared to the same quarter last year. During the same quarter last year, the company earned ($2.47) EPS.

What ETFs hold Sage Therapeutics' stock?

ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL) and Virtus LifeSci Biotech Products ETF (BBP) . AdvisorShares Dorsey Wright Short ETF (DWSH) .

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA) , AbbVie (ABBV) , Micron Technology (MU) , Alibaba Group (BABA) , Advanced Micro Devices (AMD) , Gilead Sciences (GILD) , Netflix (NFLX) , Roku (ROKU) , QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY) .

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.26%), Hennion & Walsh Asset Management Inc. (0.11%), Allspring Global Investments Holdings LLC (0.08%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Barry E Greene, Barry E Greene , Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas. View institutional ownership trends .

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Lowest-Rated StocksLowest-Rated

NASDAQ:SAGE

Sage Therapeutics (SAGE) Stock Price, News & Analysis

→ top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad)

Free SAGE Stock Alerts

$13.58

-0.42 (-3.00%)

(As of 04:00 PM ET)

Compare

Today's Range: $13.56
▼
$14.97
50-Day Range: $12.57
▼
$25.41
52-Week Range: $10.92
▼
$59.99

Volume: 1.41 million shs
Average Volume: 1.02 million shs
Market Capitalization: $816.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $39.28

Get Sage Therapeutics alerts:

Sage Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.12 Rating Score
Upside/Downside: 189.2% Upside
$39.28 Price Target
Short Interest: Bearish
18.98% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.66
Upright™ Environmental Score
News Sentiment: -0.35
Based on 24 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($6.30) to ($4.53) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.92 out of 5 stars

Medical Sector

183rd out of 907 stocks

Biotechnology Industry

4th out of 15 stocks

4.1

Analyst's Opinion

Consensus Rating
Sage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.12, and is based on 3 buy ratings, 13 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Sage Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
18.98% of the float of Sage Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Sage Therapeutics has a short interest ratio ("days to cover") of 9.2.
Change versus previous month
Short interest in Sage Therapeutics has recently increased by 8.26%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Sage Therapeutics does not currently pay a dividend.
Dividend Growth
Sage Therapeutics does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Sage Therapeutics has received a 65.22% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Antidepressants" and "Clinical research services for mental health" products. See details.
Environmental Sustainability
The Environmental Impact score for Sage Therapeutics is -1.66.

1.5

News and Social Media Coverage

News Sentiment
Sage Therapeutics has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 24 news articles for Sage Therapeutics this week, compared to 5 articles on an average week.
Search Interest
Only 5 people have searched for SAGE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
5 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sage Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.50% of the stock of Sage Therapeutics is held by insiders.
Percentage Held by Institutions
99.22% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sage Therapeutics are expected to grow in the coming year, from ($6.30) to ($4.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sage Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sage Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sage Therapeutics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Traders Agency

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

About Sage Therapeutics Stock (NASDAQ:SAGE)

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SAGE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SAGE Stock News Headlines

April 25, 2024 | investorplace.com

SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024

April 25, 2024 | markets.businessinsider.com

SAGE Therapeutics, Inc. Q1 Loss decreases, but misses estimates

April 25, 2024 | Traders Agency (Ad)

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

April 25, 2024 | finance.yahoo.com

Sage Therapeutics Inc (SAGE) Q1 2024 Earnings: Mixed Results Amidst Pipeline Progress

April 25, 2024 | businesswire.com

Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

April 24, 2024 | markets.businessinsider.com

Here's what to expect from Sage Therapeutics's earnings report